Â鶹´«Ã½

, director of laryngology research at Mass Eye and Ear, has been awarded an $11.9 million P50 Clinical Research Center Grant from the National Institute on Deafness and Other Communicable Disorders (NIDCD) of the National Institute of Health (NIH) to form a new multidisciplinary center across four academic medical institutions that will be committed to conducting research on laryngeal dystonia and voice tremor, two debilitating neurological voice disorders.

The new center will include Mass Eye and Ear and Massachusetts General Hospital, both members of Mass General Brigham, University of California San Francisco (UCSF) and the University of Utah and will involve clinicians and scientists in neuroscience, otolaryngology—head and neck surgery, speech-language pathology, neurology, neurosurgery and radiology.

“Laryngeal dystonia and voice tremor are chronic, debilitating conditions that affect voice and speech production and significantly impact the quality of life of an affected individual. These conditions often lead to devastating challenges in everyday communication, both personally and professionally,” said Dr. Simonyan. “There is an urgent need to better understand the causes of various clinical presentations of these disorders so we are well-powered to develop new and effective diagnostic tools and treatments for these patients.”

Dr. Simonyan, who is also an associate neuroscientist at MGH Neurology and associate professor of Otolaryngology–Head and Neck Surgery at Harvard Medical School, will serve as program director of this newly-established center. Site principal investigators include: director of Functional Neurosurgery at MGH; clinic director for the Voice Disorders Center at the University of Utah; director of the Speech Neuroscience Laboratory at UCSF, and , director of the Biomagnetic Imaging Laboratory at USCF.

The P50 grant will also support Mass Eye and Ear physician-scientists in the Department of Otolaryngology—Head and Neck Surgery, , , and and MGH Neurology physician-scientists and .

“This is an incredible, well-earned accomplishment for Dr. Simonyan, who has distinguished herself as an international expert in laryngeal dystonia and voice tremor,” said , Chief of the Departments of Otolaryngology–Head and Neck Surgery at Mass Eye and Ear and MGH. “Funding from the grant will have a global impact on patients suffering with these neurological voice disorders.”

Debilitating disorders affecting speech

Laryngeal dystonia, also known as spasmodic dysphonia, is characterized by involuntary spasms in the vocal folds, resulting in patients sounding strained, strangled, or breathy when they speak. Voice tremor causes involuntary oscillations of the vocal folds and upper respiratory tract that result in a shaky, unstable quality of voice.

These diseases often co-occur, masking the clinical presentations of each other and complicating their diagnosis and subsequent treatment. The current treatment of both laryngeal dystonia and voice tremor is mostly limited to the temporary symptom relief with repeated injections of botulinum toxin into the affected muscles or the off-label use of certain oral medications.

“The current diagnostic and treatment options for patients with laryngeal dystonia and voice tremor are very limited and, in many cases, not effective, presenting a clinical challenge for both physicians and patients” said Dr. Simonyan. “Our Center will leverage the multidisciplinary expertise of its investigators and combine state-of-the art methodologies to understand the causes of these disorders for their improved diagnosis and clinical care.”

Prolific dystonia researcher

Dr. Simonyan has devoted much of her career to studying the neural mechanisms of normal and disordered voice and speech production. She currently leads several projects investigating novel diagnostic algorithms and new treatments for laryngeal dystonia and voice tremor.

Among these, Dr. Simonyan recently developed a deep-learning platform called that diagnoses dystonia with 98.8 percent accuracy in 0.36 seconds based on a neural biomarker. This artificial intelligence platform is the first technology of its kind to provide an objective diagnosis for different forms of dystonia.

She is also leading a phase 2/3 clinical trial at Mass Eye and Ear on a new oral drug, sodium oxybate, for the treatment of laryngeal dystonia and voice tremor. The drug mimics the effects of alcohol, which has previously been found to relieve dystonic symptoms.

Dr. Simonyan was recently awarded a separate NIH/NIDCD grant to initiate a phase 1 clinical trial with the use of brain-computer interfaces for rehabilitation of patients with laryngeal dystonia.

“This new P50 Center grant for Dr. Simonyan and her colleagues has the potential to be a transformative addition to her body of work aimed at increasing our scientific understanding of laryngeal dystonia and other neurological voice disorders,” said , Chief Scientific Officer at Mass Eye and Ear.

About Mass Eye and Ear

Massachusetts Eye and Ear, founded in 1824, is an international center for treatment and research and a teaching hospital of Harvard Medical School. A member of , Mass Eye and Ear specializes in ophthalmology (eye care) and otolaryngology–head and neck surgery (ear, nose and throat care). Mass Eye and Ear clinicians provide care ranging from the routine to the very complex. Also home to the world's largest community of hearing and vision researchers, Mass Eye and Ear scientists are driven by a mission to discover the basic biology underlying conditions affecting the eyes, ears, nose, throat, head and neck and to develop new treatments and cures. In the 2021–2022 “Best Hospitals Survey,” U.S. Â鶹´«Ã½ & World Report ranked Mass Eye and Ear #4 in the nation for eye care and #2 for ear, nose and throat care. For more information about life-changing care and research at Mass Eye and Ear, visit our blog, , and follow us on ,  and .